Trial Profile

A Phase 1 study of agenT-797 in Graft-versus-Host Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGENT-797 (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions

Most Recent Events

14 Nov 2024 According to a MiNK Therapeutics media release, the company is advancing initiation of Phase 1 trial with external financial support to investigate agenT-797 for the treatment of GvHD, in collaboration with leading research institutions in the U.S. and EU for dosing to start in 2025.
19 Aug 2024 New trial record
13 Aug 2024 According to MiNK media release activation of this study is planned for 2Q 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com